(Reuters) -Eli Lilly hit $1 trillion in market value on Friday, making it the first drugmaker to enter the exclusive club dominated by tech giants and underscoring its rise as a weight-loss powerhouse.
Here are some reactions to Lilly joining the trillion dollar club:
EVAN SEIGERMAN, ANALYST AT BMO CAPITAL MARKETS
"The current valuation points to investor confidence in the longer-term durability of the company's metabolic health franchise. It also suggests that investors prefer Lilly over Novo in the obesity arms race. Taking a step back, we're also seeing money rotate into the sector as investors may be worried about an AI bubble."
HANK SMITH, DIRECTOR & HEAD OF INVESTMENT STRATEGY AT LILLY SHAREHOLDER HAVERFORD TRUST
"Investors have historically liked secure earnings growth and (Eli Lilly) is the only large cap pharma that has that kind of earnings profile."
(Reporting by Siddhi Mahatole and Shashwat Chauhan in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
Instructions to Warmly greet Certainty and Appeal - 2Vote In favor of Your #1 Compelling Female Producer
- 3Track down the Ideal Weight reduction Methodology for Your Way of life
- 4You finally got a doctor's appointment. Here's how to get the most out of it
- 5Illumina unveils dataset to speed up AI-powered drug discovery
- Steven Spielberg's 'Disclosure Day' trailer drops: What we know about the alien movie
- Giude to Best Web based Learning Stage
- Reports: Germany plans expansion of foreign intelligence powers
- NASA astronauts take new moonsuit for a swim | Space photo of the day for Nov. 28, 2025
- Figure out How to Pick a Crematorium: Key Contemplations.
- The wolf supermoon will kick off 2026 with a celestial bang. Here's when and how to see it.
- 2025 Was Another Exceptionally Hot Year
- Uncover the Manageable Fish Practices: Sea agreeable Feasting
- As tetanus vaccination rates decline, doctors worry about rising case numbers
